Search

Displaying results 1901 - 1910 of 8573 in total
  1. Drug

    Nitrous acid

    go.drugbank.com/drugs/DB09112
    ApprovedInvestigational

    Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning.

  2. Drug

    Ozanimod

    go.drugbank.com/drugs/DB12612
    ApprovedInvestigational

    It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.

  3. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

  4. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.

  5. Drug

    Dasatinib

    go.drugbank.com/drugs/DB01254
    ApprovedInvestigational

    [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186]

    Synonyms: BMS dasatinib
  6. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia

  7. Drug

    Spiramycin

    go.drugbank.com/drugs/DB06145
    ApprovedInvestigationalWithdrawn

    Spiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987.

  8. Drug

    Triazavirin

    go.drugbank.com/drugs/DB15622
    Investigational

    [A191709,A191625,A191916] It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. … Triazavirin is a guanine nucleotide analog antiviral originally developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain.

  9. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

  10. Drug

    Prussian blue

    go.drugbank.com/drugs/DB06783
    Approved

    It is orally administered for clinical purposes to be used as an antidote for certain kinds of heavy metal poisoning, such as thallium and radioactive isotopes of caesium. … Prussian blue is described as a deep blue pigment that is produced when the oxidation of ferrous ferrocyanide salts occurs.